The U.S. Food and Drugs Administration (FDA) has just approved the use of Walloon-based company, Cefaly's technology for the acute treatment of migraines. The company has developed a product called the "Cefaly accurate" to treat migraines.
Cefaly already offers a device for preventing migraines but this can only be used as a preventative in the United States which will not be the case with "Cefaly accurate". Indeed, Cefaly's latest product can be used to treat migraine or headache attacks.
The device has just been approved by the U.S. FDA, the product will be marketed in the States shortly and in Europe in 2018.
Currently, 60% of Cefaly products made entirely in Wallonia are sold in the United States.
"With this new authorisation for the acute treatment", explained Pierre Rigaux, CEO of Cefaly (currently 20 employees), "the potential market is increased tenfold."
Nearly 25% of the population in the Walloon region suffer from migraines according to a recent study and these devices offer an alternative to drug-based treatments as they are subject to fewer side effects. It is also possible to combine the two.
Alongside this major news, Cefaly opened its new premises at Sart-Tilman. Partly financed by the ERDF and Wallonia, these new premises were needed for the company's development. The large plot of land available to the company leaves room for possible expansion in the next few years.
Cefaly's next aim is to have its products recognised and approved for partial reimbursement by the various national health systems.
